For the second year in a row, HBSS has been named to the National Law Journal' prestigious "Plaintiff' Hot List," an award given to the top 12 plaintiff firms who "racked up impressive verdicts and settlements in the usual areas like securities fraud and explored fresh ground against self-serving managers and controlling shareholders in corporate deal-making."

HBSS was singled out for its work calling the pharmaceutical industry to task for allegedly inflating the price of many brand name drugs. So far HBSS has recovered more than $100 million in settlements and verdicts with some of the named defendants including AstraZeneca, Bristol Myers-Squibb and GlaxoSmithKline. More - and potentially larger - verdicts are expected in related cases.

The firm was also lauded for its work in a similar case involving FirstDatabank, a case that has already saved consumers an estimated $4 billion in prescription costs in a settlement reached in early June 2007.